Endometrial Cancer Risk: Advil And Other NSAIDs Linked To Higher Death Rate
Scientists have carried out a lot of recent research on the regular use of over-the-counter non-steroidal inflammatory drugs NSAIDs), such as aspirin and ibuprofen.
A new study led by The Ohio State University Comprehensive Cancer Center has linked consistent, long-term use of NSAIDs with an increased risk of dying in patients diagnosed with Type 1 endometrial cancers.
Read: Anti-Inflammatory Drugs For Depression? The Link You Need To Know About
A multi-institutional team of cancer researchers carried out an observational study of 4,000 patients and found that regular NSAID use and the risk of dying from endometrial cancer, according to Medical XPress.
Researchers found that using NSAIDs daily was associated with a 66 percent increased risk of dying from endometrial cancer among women with Type 1 endometrial cancers, which is typically a less-aggressive form of the disease.
"There is a increasing evidence that chronic inflammation is involved in endometrial cancer and progression and recent data suggests that inhibition of inflammation through NSAID use plays a role," said co-lead author of the study Theodore Brasky, PhD, Medical XPress reported.
"This study identifies a clear association that merits additional research to help us fully understand the biologic mechanisms behind this phenomenon,” he added. “Our finding was surprising because it goes against previous studies that suggest NSAIDs can be used to reduce inflammation and reduce the risk of developing or dying from certain cancers, like colorectal cancer."
Early diagnosis can increase the chances of survival. The early signs of endometrial cancer, Mayo Clinic says, can include abnormal vaginal bleeding between periods or after menopause; pelvic pain and an “abnormal, watery or blood-tinged discharge from your vagina.”
Source: Brasky TM, Felix AS, Cohn DE, McMeekin S, Mutch DG, Creasman WT, Thaker PH, et al. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. Journal of the National Cancer Institute. 2016.
See Also:
